TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01725802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa solution for SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa solution for SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00318240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: Treatment of Radiation failure in Prostate Cancer
Study: NCT03521154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib 80mg/40mg
Description: The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Osimertinib 80mg/40mg
Description: The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met
Study: NCT03701646

Intervention type: DEVICE
Intervention: Measurement by Clearsight device
Description: Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements.
Study: NCT03840213

Intervention type: BEHAVIORAL
Intervention: Filling a questionnaire and interviewDescription
Description: The questionnaire focuses on the dietary practices of patients treated with chemotherapy. It consists of 35 questions, completing an average of 20 minutes.~Interviews will be conducted with patients who have changed their diet since the beginning of their treatment in order to further develop the results of the quantitative survey.
Study: NCT02864264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986184
Study: NCT02864264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986184
Study: NCT04173182

Intervention type: DIAGNOSTIC_TEST
Intervention: Probe-based confocal laser endomicroscopy evaluation
Description: Colonoscopy with confocal laser endomicroscopy evaluation of the peridiverticular and colonic mucosa on patients with diverticular disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Probe-based confocal laser endomicroscopy evaluation
Description: Colonoscopy with confocal laser endomicroscopy evaluation of the peridiverticular and colonic mucosa on patients with diverticular disease
Study: NCT00419055

Intervention type: PROCEDURE
Intervention: Early discharge after percutaneous coronary intervenntion
Description: Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.

Intervention type: PROCEDURE
Intervention: Early discharge after percutaneous coronary intervenntion
Description: Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
Study: NCT03396887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: U Control Drink Smartphone Application
Description: The smartphone application comprises five recovery focused features: supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, craving management and gamification.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will receive treatment as usual.
Study: NCT02957513

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging (TM)
Description: As specified in the arm description above

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging (TM)
Description: As specified in the arm description above

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coaching (HC)
Description: As specified in the arm description above

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Description: As specified in the arm description above

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EC)
Description: As specified in the arm description above
Study: NCT00745329

Intervention type: OTHER
Intervention: sperm quality test
Description: All participants will undergo sequential sperm quality tests and blood tests
Study: NCT02348905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR Gel 40 units twice weekly
Description: ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR Gel 80 units twice weekly.
Description: ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
Study: NCT04719858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #LIFEGOALS
Description: Digital health behaviour change intervention including:~1. self-regulation component with Fitbit: goal setting, monitoring, feedback;~2. narrative component: every week participants receive a new episode (2-5 minutes) of a youth series modeling the target behaviours;~3. chatbot component: automated virtual coach that will send encouraging messages and give an automated answer to user questions.~Participants install the #LIFEGOALS app on their own mobile phone and are asked to use the app during 12 consecutive weeks. Three times per week a notification will be sent to encourage engagement with the intervention.
Study: NCT01625104

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non Intervention
Description: Business as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agressive Intervention Process Improvement Strategies
Study: NCT03084549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Ropivacaïne
Description: Administration of Ropivacaïne in the margins of the episiotomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Administration of placebo
Description: Administration of placebo in the margins of the episiotomy
Study: NCT03284567

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Football fitness
Description: The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., \< 5°C or heavy rain) training will be performed indoors
Study: NCT02646358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepoloxamer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepoloxamer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepoloxamer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepoloxamer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepoloxamer
Study: NCT02949375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo gel capsule to be taken daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator:4.5mg GRI-0621
Description: 4.5mg GRI-0621 gel capsule to be taken daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: 6.0mg GRI-0621
Description: 6.0mg GRI-0621 gel capsule to be taken daily for 28 days
Study: NCT00541268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICD
Description: Intracardioverter defibrillators from 2 different manufacturers
Study: NCT02679807

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis subsp. lactis Bl-04

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Study: NCT04235439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gan & Lee Insulin Lispro Injection
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gan & Lee Insulin Lispro Injection
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gan & Lee Insulin Lispro Injection
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
Study: NCT04383093

Intervention type: DRUG
Intervention: Tadalafil 5mg
Description: Combination therapy of daily tadalafil plus tamsulosin
Study: NCT03800030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-gamma tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-gamma tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-gamma tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-gamma tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-gamma tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-gamma tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta tACS
Description: NeuroConn technologies, direct current-stimulator plus
Study: NCT01661868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Tablet formulation will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Tablet formulation will be used.
Study: NCT03715959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration of Breast
Description: Undergo NAF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo NAF
Study: NCT03361072

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy
Description: Milk, peanut or egg oral immunotherapy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy
Description: Milk, peanut or egg oral immunotherapy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy
Description: Milk, peanut or egg oral immunotherapy
Study: NCT00436293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m²

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m²
Study: NCT01902862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m\^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as intravenous infusion as 375 mg pert m\^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
Study: NCT01989182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiration Valve System

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Study: NCT03800030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tACS
Description: NeuroConn technologies, direct current-stimulator plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tACS
Description: NeuroConn technologies, direct current-stimulator plus
Study: NCT04595643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of different dysphagia training modalities
Description: Neuromuscular electrical stimulation, Masako exercises, Mendelsohn maneuver, chin down, mobilization, shaker exercises, eating different food consistencies.
Study: NCT01989182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Study: NCT05232656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Discharge Checklist and Patient Safety Dashboard
Description: Pre-discharge preparation checklist for patients to assess discharge readiness. Patient safety dashboard for clinicians to proactively identify at-risk patients.
Study: NCT02569346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triumeq
Description: Single-dose Triumeq as a whole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triumeq
Description: Single-dose Triumeq as a whole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triumeq crushed + breakfast
Description: Single-dose crushed and suspended tablet of Triumeq

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triumeq crushed + breakfast
Description: Single-dose crushed and suspended tablet of Triumeq

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triumeq crushed + drip feed
Description: Drip feed followed by single-dose crushed and suspended tablet of Triumeq

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triumeq crushed + drip feed
Description: Drip feed followed by single-dose crushed and suspended tablet of Triumeq
Study: NCT00541268

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical treatment
Description: ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
Study: NCT02599480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron
Description: 50 mg daily during 12 months

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Echocardiography
Description: Echocardiography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Echocardiography

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac MRI
Description: Cardiac MRI
Study: NCT02103036

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Stability Exercises (CSE)
Description: The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Back School
Description: The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.~Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.~Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infra-red
Description: Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infra-red
Description: Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
Study: NCT02599480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac MRI
Description: Cardiac MRI

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Maximal exercise capacity
Description: Maximal exercise capacity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maximal exercise capacity
Description: Maximal exercise capacity

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling for study assessments and future exploratory studies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling for study assessments and future exploratory studies.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endothelial function measurement
Description: EndoPAT assessment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial function measurement
Description: EndoPAT assessment

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: 18FDG-PET
Description: PET scanning for beige/brown fat activation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18FDG-PET
Description: PET scanning for beige/brown fat activation
Study: NCT00769236

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling and biopsy
Description: Biopsy and blood : Research for various antibodies

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and blood sampling
Description: Biopsy and blood : research for various antibodies

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and blood sampling
Description: Blood and biopsy : research for various antibodies
Study: NCT02941289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: visual search performance of everyday objects in realistic scenes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: visual search performance of everyday objects in realistic scenes
Study: NCT03084289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63-METRAP
Description: The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63-METRAP
Description: The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.
Study: NCT03731403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI varnish
Description: CPP- ACP with 5 % sodium fluoride GC
Study: NCT04190316

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of fecal RA and environmental contamination of ESBL-PE carrier in ICU
Description: ESBL-PE carriers included in the study will be sampled for evaluation of their fecal RA of ESBL-PE on day 0, 3, 5, 7, 10, 14 and weekly till day 30 or their discharge from ICU. Urine and respiratory samples will be collected on the same day to identify multiple-site colonization with ESBL-PE. Seven samples of patient care environment will be performed 2-times a week till day 30 or discharge of the patient from the ICU.
Study: NCT03084289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63-METRAP
Description: The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63-METRAP
Description: The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63-METRAP
Description: The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.
Study: NCT03731403

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI varnish
Description: CPP- ACP with 5 % sodium fluoride GC